IC
XLRN

Ikarian Capital’s Acceleron Pharma XLRN Stock Holding History

Ikarian Capital’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-239,249
Closed -$23.1M – 215
2020
Q1 		$21.5M Buy
+239,249
New +$18.6M 1.62% 10

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ikarian Capital's XLRN Position: Q2 2020 in Review

Ikarian Capital sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 239,249 shares — an estimated $23.1M sold.

Ikarian Capital first reported a position in XLRN in Q1 2020 and held it in 1 quarter. The position peaked at $21.5M in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

  • Ikarian Capital reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
  • Ikarian Capital sold 239,249 Acceleron Pharma shares in Q2 2020, an estimated $23.1M.
  • Ikarian Capital first reported a position in Acceleron Pharma in Q1 2020 and held it in 1 quarter.
  • Ikarian Capital's Acceleron Pharma position peaked at $21.5M in Q1 2020.
  • 242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.